Silo Pharma (SILO) risk factors
Item 1A of every Silo Pharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors64 risks17 new2 dropped4 reworded
Silo Pharma added numerous risks regarding a new cryptocurrency treasury strategy, including regulatory classification, staking, and custody. Share counts and warrant overhang shifted significantly, with warrant counts rising from 2.2 million to 10.2 million.
Filed Mar 27, 2026 - FY2024 10-K risk factors49 risks
Silo Pharma relies entirely on raising external capital to fund development of early-stage central nervous system therapeutics and psychedelics. Operations depend heavily on licenses from institutions like Columbia University and the University of Maryland, Baltimore. Regulatory hurdles surrounding controlled substances such as psilocybin and psilocin pose major threats to commercialization.
Filed Mar 28, 2025